Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom. more
Time Frame | TCBP | Sector | S&P500 |
---|---|---|---|
1-Week Return | 16.39% | -2.06% | -0.55% |
1-Month Return | 11.46% | -1.92% | 2.72% |
3-Month Return | -89.76% | -10.4% | 7.66% |
6-Month Return | -92.83% | -4.6% | 10.15% |
1-Year Return | -97.39% | 4.06% | 27.53% |
3-Year Return | -100% | 1.94% | 32.31% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 3.43M | 1.98M | 1.98M | 3.84M | - | [{"date":"2019-12-31","value":89.14,"profit":true},{"date":"2020-12-31","value":51.47,"profit":true},{"date":"2021-12-31","value":51.47,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Gross Profit | 3.43M | 1.98M | 1.98M | 3.84M | - | [{"date":"2019-12-31","value":89.14,"profit":true},{"date":"2020-12-31","value":51.47,"profit":true},{"date":"2021-12-31","value":51.47,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 10.07M | 8.32M | 13.52M | 124.90K | 6.91M | [{"date":"2019-12-31","value":74.44,"profit":true},{"date":"2020-12-31","value":61.5,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":0.92,"profit":true},{"date":"2023-12-31","value":51.12,"profit":true}] |
Operating Income | (6.62M) | (6.89M) | (7.29M) | (12.08M) | (14.24M) | [{"date":"2019-12-31","value":-661863900,"profit":false},{"date":"2020-12-31","value":-688673900,"profit":false},{"date":"2021-12-31","value":-728702400,"profit":false},{"date":"2022-12-31","value":-1208399700,"profit":false},{"date":"2023-12-31","value":-1423932300,"profit":false}] |
Total Non-Operating Income/Expense | (528.92K) | (582.07K) | (11.13M) | 2.06M | 7.16M | [{"date":"2019-12-31","value":-7.39,"profit":false},{"date":"2020-12-31","value":-8.13,"profit":false},{"date":"2021-12-31","value":-155.5,"profit":false},{"date":"2022-12-31","value":28.74,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (6.89M) | (6.63M) | (14.98M) | (3.03M) | (7.00M) | [{"date":"2019-12-31","value":-689404900,"profit":false},{"date":"2020-12-31","value":-662984400,"profit":false},{"date":"2021-12-31","value":-1498346700,"profit":false},{"date":"2022-12-31","value":-303360100,"profit":false},{"date":"2023-12-31","value":-699568200,"profit":false}] |
Income Taxes | (826.07K) | 1.17M | 1.41M | 1.72M | (1.09M) | [{"date":"2019-12-31","value":-48.03,"profit":false},{"date":"2020-12-31","value":68.14,"profit":true},{"date":"2021-12-31","value":81.83,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-63.3,"profit":false}] |
Income After Taxes | (6.07M) | (7.80M) | (16.39M) | (4.75M) | (5.91M) | [{"date":"2019-12-31","value":-606798400,"profit":false},{"date":"2020-12-31","value":-780177200,"profit":false},{"date":"2021-12-31","value":-1639100900,"profit":false},{"date":"2022-12-31","value":-475360100,"profit":false},{"date":"2023-12-31","value":-590695300,"profit":false}] |
Income From Continuous Operations | (6.07M) | (5.46M) | (13.58M) | (1.39M) | (5.91M) | [{"date":"2019-12-31","value":-606798400,"profit":false},{"date":"2020-12-31","value":-545791600,"profit":false},{"date":"2021-12-31","value":-1357592500,"profit":false},{"date":"2022-12-31","value":-138970600,"profit":false},{"date":"2023-12-31","value":-590695300,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (6.07M) | (5.46M) | (13.58M) | (1.31M) | (5.91M) | [{"date":"2019-12-31","value":-606798400,"profit":false},{"date":"2020-12-31","value":-545791600,"profit":false},{"date":"2021-12-31","value":-1357592500,"profit":false},{"date":"2022-12-31","value":-131360100,"profit":false},{"date":"2023-12-31","value":-590695300,"profit":false}] |
EPS (Diluted) | - | - | (9.37) | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-936.69,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
TCBP | |
---|---|
Cash Ratio | 0.28 |
Current Ratio | 1.12 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
TCBP | |
---|---|
ROA (LTM) | -108.92% |
ROE (LTM) | -1217.48% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
TCBP | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.71 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.29 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
TCBP | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.51 |
P/B | 1.51 |
Price/FCF | NM |
EV/R | 1.83 |
EV/Ebitda | NM |
TC BioPharm Holdings PLC (TCBP) share price today is $0.65
Yes, Indians can buy shares of TC BioPharm Holdings PLC (TCBP) on Vested. To buy TC BioPharm Holdings PLC from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in TCBP stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of TC BioPharm Holdings PLC (TCBP) via the Vested app. You can start investing in TC BioPharm Holdings PLC (TCBP) with a minimum investment of $1.
You can invest in shares of TC BioPharm Holdings PLC (TCBP) via Vested in three simple steps:
The 52-week high price of TC BioPharm Holdings PLC (TCBP) is $41.5. The 52-week low price of TC BioPharm Holdings PLC (TCBP) is $0.44.
The price-to-earnings (P/E) ratio of TC BioPharm Holdings PLC (TCBP) is
The price-to-book (P/B) ratio of TC BioPharm Holdings PLC (TCBP) is 1.51
The dividend yield of TC BioPharm Holdings PLC (TCBP) is 0.00%
The market capitalization of TC BioPharm Holdings PLC (TCBP) is $360.37K
The stock symbol (or ticker) of TC BioPharm Holdings PLC is TCBP